Nuvelo Appoints Vice President of Regulatory Affairs and Quality Assurance
Tuesday August 5, 9:30 am ET
SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News) today announced the appointment of Hana B. Moran, PhD, as vice president of regulatory affairs and quality assurance.
Dr. Moran brings over twenty years of development, regulatory affairs and quality assurance experience to Nuvelo. Most recently, Dr. Moran served as vice president, regulatory affairs and quality assurance for Lipid Sciences, Inc., and prior to that she held senior management positions at both BioMedicines, Inc. and SangStat Medical Corp. From 1983 to 1994, Dr. Moran served in various regulatory affairs and quality assurance roles at companies including Athena Neurosciences, Inc., Fujisawa Pharmaceutical Company, Boehringer-Ingelheim, Inc. and G.D. Searle & Co. She has received several awards including the National Institutes of Health Research Service Award and is involved in the American Association of Pharmaceutical Sciences, the Drug Information Association and the Regulatory Affairs Professional Society. Dr. Moran earned her master's degree at the Slovak Technical University in Czechoslovakia and her PhD at the Weizmann Institute of Science in Israel.
"With clinical development efforts successfully moving forward, we have been strategically building our team," said Dr. Ted W. Love, president and chief executive officer of Nuvelo. "The addition of Dr. Moran will provide significant expertise in working with the FDA that is invaluable to the progress of our development programs."
About Nuvelo
Nuvelo, Inc., formed by the merger of Hyseq Pharmaceuticals, Inc. and VARIAGENICS, Inc., is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's lead product candidate, alfimeprase, is partnered with Amgen and is currently in two Phase II trials in both peripheral arterial occlusion and catheter occlusion. Additional programs include drug discovery focused on immunotherapeutics and secreted proteins.
Information about Nuvelo is available at our new Web site at www.nuvelo.com or by phoning 408-215-4000.
Statements contained in this press release which are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and "potential," among others. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that we may not successfully integrate the VARIAGENICS business following our recent merger, uncertainties relating to drug discovery, clinical development processes and the development and commercialization of our molecular diagnostics technology; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to our ability to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and described in more detail in Nuvelo, Hyseq and VARIAGENICS filings with the SEC, including without limitation Nuvelo's annual report on Form 10-K and the related Form 10-K/A for the year ended December 31, 2002 and Nuvelo's quarterly report on Form 10-Q for the quarter ended March 31, 2003. We disclaim any intent or obligation to update these forward-looking statements.
Source: Nuvelo, Inc. |
